The relationship between epidermal growth factor receptor (EGFR) mutation status and EGFR-tyrosine kinase inhibitors (TKI)
ef?cacy in non-small cell lung cancer (NSCLC) patients has been well established. However, there is no available standard to
define the optimal testing method and specimen type required for the detection of EGFR mutations. In this study, we compare results of ADx-amplification refractory mutation system (ARMS) and direct sequencing for the detection of EGFR mutation and prediction of EGFR-TKI efficacy for surgery and biopsy tumor tissues in 158 NSCLC patients.

Though the possibility of using malignant pleural effusions (MPEs) as alternatives for metastatic pleural tumor tissues (MPTTs) in epidermal growth factor receptor (EGFR) mutation test has been examined, due to the lack of studies comparing the results in matching MPEs and MPTTs, the clinical value of MPEs for advanced adenocarcinoma patients with pleural effusions is not
confirmed.

Compared with FISH and qRT-PCR analyses, immunohistochemistry (IHC) is the preferred screening test in most pathology
practices for ALK-rearrangement detection. With 100% sensitivity and 98% specificity, the VENTANA ALK (D5F3) IHC assay has been approved in the EU and some Asian countries for ALK-rearrangement detection. However, an automated Ventana IHC
platform is not available in most pathology labs. In this study, we evaluated the applicability of conventional IHC with D5F3
antibody in routine pathological practice and proposed detection methods and procedures that ensure that patients with
ALK+ are not missed.

Activating mutations of epidermal growth factor receptor (EGFR) could predict response to tyrosine kinase inhibitor(TKI)
treatment in patients with non-small cell lung cancer (NSCLC). However, the detection of EGFR mutation is frequently
challenging in clinical practice for the lack of tumor tissue.The aim of this study was to investigate the feasibility of performing EGFR mutation testing on various types of liquid-based cytology (LBC) samples.

棘皮動物微管相關樣蛋白4 ( echinoderm microtubule associated protein-like 4 , EML4）與間變性淋巴瘤激酶(anaplastic lymphoma kinase，ALK)融合基因是非小細胞肺癌（NSCLC）中繼表皮生長因子受體（EGFR）突變、KRAS突變后的又一特異性腫瘤驅動基因，近期，針對EML4-ALK為靶點的克哩替尼（crizotinib）在治療晚期NSCLC中已取得了令人矚目的療效，因此使用準確、可靠且易于臨床開展的EML4-ALK融合基因檢測方法是決定患者能否應用克哇替尼治療的先決條件。2013年3月，基于逆轉錄聚合酶鏈反應（RT-PCR）技術的國產EML4-ALK檢測試劑盒獲得中國食品藥品監督管理總局（CFDA）批準上市。本文主要介紹RT-PCR技術在EML4-ALK融合基因篩查中的應用。

探討非小細胞肺癌( NSCLC）中EML4-ALK融合基因的存在情況及其與患者臨床病理特征的關系。